Merck

Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook

Merck & Co. (NYSE: MRK) is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid‑stage data for heart drug Winrevair, and fresh deal‑making have pushed the share price close to its

30 November 2025

Merck Stock (MRK) Outlook Before the December 1, 2025 Market Open: Rally, Ratings and Pipeline Catalysts

Merck & Co., Inc. (NYSE: MRK) heads into the Monday, December 1, 2025 market open riding one of the strongest monthly rallies in the S&P 500, powered by upbeat earnings, dividend growth and a string of bullish analyst calls focused

30 November 2025

Earnings Preview · Investment Strategies · Market Outlook · NYSE:MRK · Pharma Industry · Stock Analysis

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are

30 November 2025

Analyst Ratings · Dividend Analysis · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As

29 November 2025

Company Updates · Healthcare Stocks · Investment Insights · NYSE:MRK · Pharmaceutical Industry · Stock Market News

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

On Friday, 28 November 2025, Merck & Co., Inc. (NYSE: MRK) continued to trade near its 52‑week highs as a wave of fresh institutional filings, bullish research notes, and recent oncology approvals kept the spotlight firmly on the pharmaceutical giant.

28 November 2025

Dividends · Financial News · Investing · NYSE:MRK · Pharmaceutical Industry · Stock Market

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck & Co., Inc. (NYSE: MRK) spent Wednesday trading just below fresh 52‑week highs, as Wall Street continues to digest a powerful mix of positive drug news, upbeat earnings, and a wave of analyst upgrades and institutional buying. Merck stock

26 November 2025

Analyst Ratings · Financial News · Investment · NYSE:MRK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25

25 November 2025

Company Upgrades · FDA Approval · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Dow 30 Today (24 November 2025): Merck and Caterpillar Lead 200‑Point Dow Jones Rally on Fed Rate‑Cut Bets

On Monday, 24 November 2025, the Dow Jones Industrial Average (Dow 30) climbed 202.86 points, or 0.44%, to 46,448.27, kicking off the holiday‑shortened week with a strong risk‑on tone. The rally was powered by healthcare and industrial heavyweights such as Merck, Caterpillar,

25 November 2025

Dow Jones · Federal Reserve · Financial News · Investing · NYSE:CAT · NYSE:MRK · Stock Market

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within

24 November 2025

Analyst Ratings · Company Earnings · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck & Co., Inc. (NYSE: MRK) is suddenly back in the market’s spotlight. On Monday, 24 November 2025, Merck’s share price surged to around $102, up roughly 4–4.5% on the day, after a bullish analyst upgrade collided with fresh regulatory

24 November 2025

Company Updates · Healthcare Industry · Investment · NYSE:MRK · Pharma News · Stock Market

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. (NYSE: MRK) is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of

22 November 2025

Company Updates · Dividends · Investment News · Pharmaceuticals · Stock Market

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

November 18, 2025 — Merck & Co. (NYSE: MRK) is trading higher today after the company reported new mid‑stage data for its cardiopulmonary medicine Winrevair (sotatercept‑csrk), fueling optimism about growth beyond Keytruda and adding momentum to last week’s acquisition of

18 November 2025

Clinical Trials · Flu Treatments · Merck News · NYSE:MRK · Pharma Partnerships · Stock Updates